We are Sorry, This Page doesn't Exist

Latest Phase 2 epilepsy study findings on ADX71149 adjunctive therapy for focal onset seizures. Partnered with Janssen, Addex Therapeutics evaluates treatment efficacy in patients with suboptimal response to standard care. read more.....»»

Boeing's turbulent trajectory continues with stock down 32% YTD. Attention shifts to Q1 earnings and new CEO appointment, pivotal for futur.....»»

Shares of Myovant Sciences Ltd. were down 5.7% in premarket trading on Wednesday after the company told investors that the Food and Drug Administration had placed a partial clinical hold on a study assessing an experimental birth c.....»»

Sarepta Therapeutics Inc. shares lost more than half their value in after-hours trading Thursday, after the company said a drug candidate produced mixed results in a clinical study......»»

Aduro (ADRO) presents updated data from an ongoing phase Ib study evaluating its STING agonist, ADU-S100 in combination with No.....»»

Aldeyra Therapeutics Inc (NASDAQ: ALDX) shares are advancing strongly Tuesday following the release of the results of a late-stage study of its drug candidate for allergic conjunctivitis. Latest R.....»»

Altimmune Inc (NASDAQ: ALT), which develops immunotherapies and vaccines, is seeing its stock surge on 15 times its average volume after the company reported the results of a midstage study of its lead candidate NasoVAX. read more.....»»

Phase Bio's stock price was up more than double in premarket trading Monday morning after the Malvern biopharmaceutical company published positive early-stage study results from one of its lead new drug candidate over the weekend The company's stock.....»»

Shares of Idera (IDRA) decline following the failure of a phase II study of its pipeline candidate, IMO-8400, on adult patients with dermatomyositis. Idera Pharmaceuticals Inc IDRA announced that the phase II clinical study, eva.....»»

Shares of Zai Lab (ZLAB) decline following the failure of a phase IIA study on its pipeline ca.....»»

A new drug meant to help rheumatoid arthritis achieved .....»»

Pfizer (PFE) and Lilly present detailed data from a phase III study on pain candidate, tanezumab. The former forms a new company for CNS treatment in alliance with Bain C.....»»

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) announced incremental positive news on its lead cannabinoid product candidate Epidiolex, sending the stock higher. read more.....»»

Eyenovia (EYEN) starts enrollment in the first phase III study of a two clinical study program to evaluate its mydriasis candidate, MicroStat. Stock rallies. .....»»

Evofem (EVFM) stock surges on positive results from a late-stage study on experimental birt.....»»

Zacks.....»»

Zacks.....»»

Gilead Sciences, Inc. (NASDAQ: GILD) is facing another setback, as its non-alcoholic steatohepatitis, or NASH, candidate Selonsertib flunked in a late-stage study. read more.....»»

Novavax, Inc. (NASDAQ: NVAX) shares were trading at less than $1 Thursday following the release of late-stage study results for its investigational vaccine candidate ResVax. read more.....»»

MariTide, formerly AMG 133, is an injectable form of drug targeting two gut hormones — gastric inhibitory polypeptide receptor, or GIP, and glucagon-like peptide 1, or GLP-1. read more.....»»